Add like
Add dislike
Add to saved papers

Evaluation of the inhibitory impact of biosynthesized silver nanoparticles using Bacillus cereus and Chromobacterium violaceum bacteria on some intestinal protozoa.

Nano materials are utilized to improve the performance of some pharmaceuticals and materials, as well as to lessen the collateral damage they cause. The purpose of this study was to look at the effect of silver nanoparticles (AgNPs) produced by bacteria on some trophozoites of intestinal parasites. The silver nanoparticles were synthesized using Bacillus cereus (BAgNPs) and Chromobacterium violaceum (ChAgNPs) bacteria. The AgNPs production was confirmed by several tests and techniques, such as electron microscopy. The results of the analysis showed that the size of these particles was within the range of 21-96.71 nm for both BAgNPs and ChAgNPs. In vitro and in vivo efficacy were tested on some trophozoites of intestinal parasites. The effect of the AgNPs on Entamoeba histolytica trophozoites in culture was significantly higher compared to metronidazole. The highest percentage of inhibition was 70.6% and 76.5% for the particles prepared from B. cereus and C. violaceum without significant differences between the two bacteria, compared to 57.6% inhibition for metronidazole. The in vivo effect of the AgNPs on Giardia lamblia exceeded that of metronidazole and led to the total disappearance of the stages from mice faeces after 3-4 days. Likewise, Tritrichomonas muris numbers were also reduced in infected mice treated with AgNPs, with the highest inhibition rate of 81.3%. From above can concluded these bacterially produced nanoparticles have proven strong efficacy, and it is possible to recommend their use independently after conducting studies on the extent of their effects on the body and proving their safety.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app